PD-L1発現率50%以上の非小細胞肺癌患者におけるカプマチニブ（INC280）とペムブロリズマブの併用療法とペムブロリズマブ単剤療法の安全性および有効性の比較

基本情報

NCT ID

NCT04139317

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

76

治験依頼者名

Novartis

概要

The purpose was to evaluate the efficacy and safety of the combination of capmatinib with pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with locally advanced or metastatic NSCLC who have PD-L1 expression ≥ 50% and have no EGFR mutation or ALK rearrangement. Capmatinib has demonstrated immunomodulatory activities when combined with an anti-PD1 antibody in preclinical tumor models irrespective of MET dysregulation. The combination of capmatinib with checkpoint inhibitors has been established to be tolerable and could provide additional clinical benefit to the subjects.

対象疾患

介入

依頼者（Sponsor）